May 14, 2014– Dendreon Corporation (NASDAQ:) announced today the presentation of two PROVENGE (sipuleucel-T) abstracts from the Phase II STAND study and the PROCEED registry, and one abstract ...

SEAL BEACH, Calif.--(BUSINESS WIRE)--Dendreon Pharmaceuticals LLC, a commercial-stage biopharmaceutical company and pioneer in the development of immunotherapy, released results of a new retrospective ...

SEAL BEACH, Calif.--(BUSINESS WIRE)--Dendreon Pharmaceuticals, a commercial-stage biopharmaceutical company and pioneer in the development of immunotherapy, announced early completion of patient ...

Is Provenge, which demonstrated only a modest survival benefit, worth the price? The median time from first infusion of sipuleucel-T to death from prostate cancer was 42.7 months. Findings from a real ...

In a study of men with metastatic castration-resistant prostate cancer, sipuleucel-T immunotherapy used at any point during treatment was associated with a decreased risk of death compared with ...

SEATTLE and WASHINGTON, Oct. 1 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced the following PROVENGE® (sipuleucel-T) data presentations taking place at the 25th International ...

– Dendreon Corporation (NASDAQ:) today announced the presentation of four PROVENGE (sipuleucel-T) abstracts and one abstract for DN24-02, an investigational active cellular immunotherapy, from ongoing ...

announced today that four abstracts featuring PROVENGE^® (sipuleucel-T) data from ongoing Phase II sequencing studies and the PROCEED registry, and two abstracts highlighting preliminary Phase II data ...

Sipuleucel-T (trade name Provenge) has been approved since September 2014 for men with metastatic prostate cancer who have few or no symptoms and do not yet require chemotherapy. In the dossier ...

Dendreon announced the approval of Provenge (sipuleucel-T suspension for intravenous infusion) for the treatment of asymptomatic or minimally symptomatic metastatic, castrate-resistant ...

The first and only immunotherapy product for advanced cancer, sipuleucel-T (Provenge), has not been widely used clinically since its launch 10 years ago, and has been largely eclipsed by two drugs ...

The efficacy and safety of degarelix, a GnRH receptor antagonist: A multicenter, randomized, maintenance dose-finding phase II study with Japanese prostate cancer patients. A phase I/II randomized ...